KRAS mutation testing of tumours in adults with metastatic colorectal cancer: a systematic review and cost-effectiveness analysis
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
KRAS mutation testing of tumours in adults with metastatic colorectal cancer: a systematic review and cost-effectiveness analysis
Authors
Keywords
-
Journal
HEALTH TECHNOLOGY ASSESSMENT
Volume 18, Issue 62, Pages 1-132
Publisher
National Institute for Health Research
Online
2014-10-16
DOI
10.3310/hta18620
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Intra-tumoral Heterogeneity ofKRASandBRAFMutation Status in Patients with Advanced Colorectal Cancer (aCRC) and Cost-Effectiveness of Multiple Sample Testing
- (2015) Susan D. Richman et al. Analytical Cellular Pathology
- QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies
- (2013) Penny F. Whiting ANNALS OF INTERNAL MEDICINE
- KRAS mutation detection by high-resolution melting analysis significantly predicts clinical benefit of cetuximab in metastatic colorectal cancer
- (2012) U Malapelle et al. BRITISH JOURNAL OF CANCER
- Influence ofKRASmutation status in metachronous and synchronous metastatic colorectal adenocarcinoma
- (2012) Jeffrey S. Rose et al. CANCER
- Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters
- (2012) Geoffrey Y. Ku et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Concordant KRAS Mutations in Primary and Metastatic Colorectal Cancer Tissue Specimens: A Meta-Analysis and Systematic Review
- (2012) Cheng-Bo Han et al. CANCER INVESTIGATION
- Effect of KRAS Mutational Status in Advanced Colorectal Cancer on the Outcomes of Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: A Systematic Review and Meta-analysis
- (2012) Albert Y. Lin et al. Clinical Colorectal Cancer
- Influence of KRAS p.G13D Mutation in Patients With Metastatic Colorectal Cancer Treated With Cetuximab
- (2012) Pablo Gajate et al. Clinical Colorectal Cancer
- Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials
- (2012) Carsten Bokemeyer et al. EUROPEAN JOURNAL OF CANCER
- Resectability and outcome with anti-EGFR agents in patients with KRAS wild-type colorectal liver-limited metastases: a meta-analysis
- (2012) F. Petrelli et al. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
- Association ofKRASG13D Tumor Mutations With Outcome in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy With or Without Cetuximab
- (2012) Sabine Tejpar et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study
- (2012) Kjell Magne Tveit et al. JOURNAL OF CLINICAL ONCOLOGY
- Sanger sequencing in routine KRAS testing: a review of 1720 cases from a pathologist's perspective
- (2012) Umberto Malapelle et al. JOURNAL OF CLINICAL PATHOLOGY
- Cost-Effectiveness Analysis of Screening for KRAS and BRAF Mutations in Metastatic Colorectal Cancer
- (2012) Ajay S. Behl et al. JNCI-Journal of the National Cancer Institute
- Cost-Effectiveness Analysis of KRAS Testing and Cetuximab as Last-Line Therapy for Colorectal Cancer
- (2012) Takeru Shiroiwa et al. Molecular Diagnosis & Therapy
- The role of cetuximab as first‐line treatment of colorectal liver metastases
- (2012) Claire Jones et al. HPB
- Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study
- (2011) C. Bokemeyer et al. ANNALS OF ONCOLOGY
- KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients
- (2011) N Knijn et al. BRITISH JOURNAL OF CANCER
- Clinical impact of anti-epidermal growth factor receptor monoclonal antibodies in first-line treatment of metastatic colorectal cancer
- (2011) Fotios Loupakis et al. CANCER
- Wild-type KRAS and BRAF could predict response to Cetuximab in Chinese colorectal cancer patients
- (2011) Jing Gao et al. Chinese Journal of Cancer Research
- Increased Detection Sensitivity for KRAS Mutations Enhances the Prediction of Anti-EGFR Monoclonal Antibody Resistance in Metastatic Colorectal Cancer
- (2011) F. Molinari et al. CLINICAL CANCER RESEARCH
- KRAS and BRAF Mutation Analysis in Metastatic Colorectal Cancer: A Cost-effectiveness Analysis from a Swiss Perspective
- (2011) P. R. Blank et al. CLINICAL CANCER RESEARCH
- 6006 ORAL Intermittent Chemotherapy (CT) Plus Continuous or Intermittent Cetuximab (C) in the First-line Treatment of Advanced Colorectal Cancer (aCRC): Results of the Two-arm Phase II Randomised MRC COIN-B Trial
- (2011) H. Wasan et al. EUROPEAN JOURNAL OF CANCER
- Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer
- (2011) Cecily P. Vaughn et al. GENES CHROMOSOMES & CANCER
- Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany
- (2011) Arthi Vijayaraghavan et al. INTERNATIONAL JOURNAL OF CANCER
- Overall and KRAS-specific results of combined cetuximab treatment and chemotherapy for metastatic colorectal cancer: a meta-analysis
- (2011) Linlin Zhang et al. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
- Cetuximab and panitumumab in KRAS wild-type colorectal cancer: a meta-analysis
- (2011) Fausto Petrelli et al. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
- Cetuximab Plus Capecitabine and Irinotecan Compared With Cetuximab Plus Capecitabine and Oxaliplatin As First-Line Treatment for Patients With Metastatic Colorectal Cancer: AIO KRK-0104—A Randomized Trial of the German AIO CRC Study Group
- (2011) Nicolas Moosmann et al. JOURNAL OF CLINICAL ONCOLOGY
- Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status
- (2011) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial
- (2011) Timothy S Maughan et al. LANCET
- Cetuximab Plus FOLFIRINOX (ERBIRINOX) as First-Line Treatment for Unresectable Metastatic Colorectal Cancer: A Phase II Trial
- (2011) E. Assenat et al. ONCOLOGIST
- Cetuximab plus FOLFOX-4 in Untreated Patients with Advanced Colorectal Cancer: A Gruppo Oncologico dell’Italia Meridionale Multicenter Phase II Study
- (2011) Giuseppe Colucci et al. ONCOLOGY
- PCN3 Cetuximab for the First-Line Treatment of Metastatic Colorectal Cancer
- (2011) R. Ubago et al. VALUE IN HEALTH
- Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up
- (2010) R. Labianca et al. ANNALS OF ONCOLOGY
- Activating KRAS Mutations and Overexpression of Epidermal Growth Factor Receptor as Independent Predictors in Metastatic Colorectal Cancer Patients Treated With Cetuximab
- (2010) Li-Chen Yen et al. ANNALS OF SURGERY
- Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases
- (2010) S. E. Baldus et al. CLINICAL CANCER RESEARCH
- Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: A meta-analysis of 22 studies
- (2010) Li-Xin Qiu et al. EUROPEAN JOURNAL OF CANCER
- Cetuximab-based therapy for metastatic colorectal cancer: a meta-analysis of the effect of K-ras mutations
- (2010) Ezzeldin M. Ibrahim et al. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
- Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
- (2010) Wendy De Roock et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Inclusion of methodological filters in searches for diagnostic test accuracy studies misses relevant studies
- (2010) Penny Whiting et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial
- (2010) Janja Ocvirk WORLD JOURNAL OF GASTROENTEROLOGY
- Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study
- (2009) Jean-Luc Raoul et al. BMC CANCER
- 6LBA Addition of cetuximab to oxaliplatin-based combination chemotherapy (CT) in patients with KRAS wild-type advanced colorectal cancer (ACRC): a randomised superiority trial (MRC COIN)
- (2009) T. Maughan et al. EJC SUPPLEMENTS
- 4004 Cetuximab plus capecitabine as first-line treatment for elderly patients (pts) with advanced colorectal cancer (mCRC). Final analysis of activity and survival according to KRAS status – the TTD-06–01 Spanish Cooperative Group trial
- (2009) F. Rivera et al. EJC SUPPLEMENTS
- 6077 A meta-analysis of the CRYSTAL and OPUS studies combining cetuximab with chemotherapy (CT) as 1st-line treatment for patients (pts) with metastatic colorectal cancer (mCRC): Results according to KRAS and BRAF mutation status
- (2009) E. Van Cutsem et al. EJC SUPPLEMENTS
- 6078 Cetuximab plus FOLFIRI in 1st-line treatment of metastatic colorectal cancer: Quality of life (QoL) analysis of patients (pts) with KRAS wild-type (wt) tumours in the CRYSTAL trial
- (2009) I. Lang et al. EJC SUPPLEMENTS
- 6079 Overall survival of patients with KRAS wild-type tumours treated with FOLFOX4± cetuximab as 1st-line treatment for metastatic colorectal cancer: The OPUS study
- (2009) C. Bokemeyer et al. EJC SUPPLEMENTS
- 6086 Induction of resectability of colorectal liver metastases (CLM) with cetuximab (Cmab) plus CPT-11/5-fluorouracil (5-FU)/leucovorin (FA)/oxaliplatin (L-OHP) (CPT-11-FFL) (POCHER trial)
- (2009) C. Garufi et al. EJC SUPPLEMENTS
- American Society of Clinical Oncology Provisional Clinical Opinion: Testing forKRASGene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy
- (2009) Carmen J. Allegra et al. JOURNAL OF CLINICAL ONCOLOGY
- A Multicenter Blinded Study to Evaluate KRAS Mutation Testing Methodologies in the Clinical Setting
- (2009) Vicki Whitehall et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial
- (2009) Gunnar Folprecht et al. LANCET ONCOLOGY
- Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
- (2009) Eric Van Cutsem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer
- (2009) Jens Neumann et al. PATHOLOGY RESEARCH AND PRACTICE
- KRAS Mutations in Primary Colorectal Cancer Tumors and Related Metastases: A Potential Role in Prediction of Lung Metastasis
- (2009) Paloma Cejas et al. PLoS One
- An empirical comparison of methods for meta-analysis of diagnostic accuracy showed hierarchical models are necessary
- (2008) Roger M. Harbord et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer
- (2008) Carsten Bokemeyer et al. JOURNAL OF CLINICAL ONCOLOGY
- Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
- (2008) Bernard Nordlinger et al. LANCET
- Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer
- (2008) Helena Linardou et al. LANCET ONCOLOGY
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now